Allogeneic hematopoietic cell transplantation is considered medically necessary to treat chronic lymphocytic leukemia or small lymphocytic lymphoma in individuals with markers of poor-risk disease (see Policy Guidelines and Rationale sections). Use of a myeloablative or reduced-intensity pretransplant conditioning regimen should be individualized based on factors that include age, the presence of comorbidities, and disease burden.
Autologous hematopoietic cell transplantation is considered investigational to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
